Medical/Pharmaceuticals
First Prescription for COSELA® (trilaciclib) Issued in China
- COSELA®, the world's first and only myeloprotection drug, was prescribed in Jilin Cancer Hospital onJanuary 28, 2023 - Simcere delivers drug to patients in 908 days from execution of license agreement to first prescription NANJING, China, Feb. 9, 2023 /PRNewswire/ -- Simcere Pharmaceutical Gr...
2023-02-09 21:00
2990
Technoderma Medicines Initiates TDM-180935 Atopic Dermatitis Clinical Program with Phase 1 Dose Escalation Trial
SAN DIEGO, Feb. 9, 2023 /PRNewswire/ -- Technoderma Medicines, Inc. ("the Company"), a clinical stage biopharmaceutical company, is pleased to report the Company has begun dosing healthy volunteer subjects in its Phase 1 clinical trial of topical TDM-180935 ointment. This first clinical trial in ...
2023-02-09 21:00
1689
AnPac Bio-Medical Science Enters into Definitive Agreement to Acquire Fresh2 Ecommerce Inc, a B2B Asian Food E-commerce Platform
Transaction expected to fuel the Company's growth in the U.S. food market NEW YORK, Feb. 9, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ: ANPC), a company with operations inthe United States andChina focused on early cancer screening and detection and plans to ...
2023-02-09 21:00
3135
GC Biopharma Receives WHO Pre-Qualification for Filling and Finish Plant in Ochang, South Korea
YONGIN, South Korea, Feb. 8, 2023 /PRNewswire/ -- GC Biopharma (006280.KS), a leading provider of biopharmaceutical products inSouth Korea, announced today that the World Health Organization (WHO) has awarded prequalification to filling and finish plant onFebruary 3 2023, located in Ochang, South...
2023-02-09 09:21
1960
ImmVira Clinical Snapshot: Intratumoral Injected OV (MVR-T3011 IT) Monotherapy Achieved Median PFS of 12.9 Months on Treatment of Melanoma
SHENZHEN, China, Feb. 8, 2023 /PRNewswire/ -- ImmVira's first intratumoral injected OV product MVR-T3011 IT has shown positive efficacy in the course of clinical studies in the U.S. andChina as of January 2023, with which the monotherapy treatment significantly prolonged PFS to a median of 12.9 m...
2023-02-09 08:00
1836
ReviR Therapeutics and Asieris Pharmaceuticals Enter into Agreement to Discover Oncology Therapeutics Based on ReviR's Comprehensive Approach to RNA-targeted Technologies
SAN FRANCISCO, Feb. 8, 2023 /PRNewswire/ -- ReviR Therapeutics, a privately held developer of a suite of small molecule RNA-targeting technologies for cancer and other genetically-defined diseases, and Asieris Pharmaceuticals, a global biopharma company specializing in discovering, developing, an...
2023-02-08 22:00
2110
SUMMIT HEALTHCARE ACQUISITION CORP. AND YS BIOPHARMA ANNOUNCE EFFECTIVENESS OF REGISTRATION STATEMENT AND EXTRAORDINARY GENERAL MEETING DATE FOR PROPOSED BUSINESS COMBINATION
* Extraordinary general meeting of Summit Healthcare Acquisition Corp.'s shareholders to be held onMarch 1, 2023 at 9:00 a.m. Eastern Time * YS Biopharma is a global biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines a...
2023-02-08 21:30
3126
Lunit and Agfa HealthCare bring breast imaging AI solution to Dubai Academic Health Corporation (DAHC) Dubai Hospital
* Dubai Academic Health Corporation (DAHC) Dubai Hospital to modernize its Breast Cancer Diagnostic and Screening program with Agfa HealthCare's RUBEE for AI framework and Lunit INSIGHT MMG algorithm * The Breast AI Analysis Package is Lunit's first application with Agfa HealthCare since form...
2023-02-08 21:05
2203
Meihua International Medical Technologies Co. Explores Application of ChatGPT Technologies to Develop Online AI Health Consultation Services
YANGZHOU, China, Feb. 8, 2023 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (NASDAQ: MHUA), a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries inChina, today announced the Company will...
2023-02-08 20:30
1637
SK bioscience Announces the Largest Investment Ever to Establish Songdo Global Research & Process Development Center
* The additional investment for the 'R&PD Center' was confirmed by the board of directors committee with a total of261 million USD * SK bioscience plans to establish a vaccine-biopharmaceutical hub, organizing a global cooperative model against new pandemics SEONGNAM, South Korea, Feb. 8, 202...
2023-02-08 20:00
2016
Infectious disease specialist Dr. Regis A. Vilchez is appointed CMO of MicuRx Pharmaceuticals, Inc.
SHANGHAI, Feb. 8, 2023 /PRNewswire/ -- Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx," 688373) announced recently that it has appointedRegis A. Vilchez, MD, PhD, an experienced R&D biopharmaceutical executive and infectious disease expert, as Chief Medical Officer of its American subsidiary, ...
2023-02-08 16:05
2423
Orion Health reinforces security credentials with HITRUST and DirectTrust accreditations
HITRUST Risk-based, 2-year Certification for Amadeus validates commitment to protecting sensitive information, while Communicate product also achieves DirectTrust™ HISP Accreditation AUCKLAND, New Zealand, Feb. 7, 2023 /PRNewswire/ -- Orion Health, a global leader in population health software, ...
2023-02-08 12:40
2111
Complete Genomics Drops Genome Sequencing Price to Sub $100 at AGBT General Meeting
DNBSEQ-T20×2*produces up to 50,000 WGS per year at a first sub hundred-dollar price per genome DNBSEQ-T7* offers an outstanding $1.5/Gb price for sequencing consumables DNBSEQ-G99* delivers a first-in-class PE150 run within 12 hours with a data output of 8- 48 Gb per run stLFR library prep ...
2023-02-07 22:00
2205
J INTS BIO, Oral TKI 'JIN-A04', poster presentation of HER2 exon20 insertion mutation in NSCLC
SEOUL, South Korea, Feb. 6, 2023 /PRNewswire/ -- J INTS BIO announced that the preclinical results of "JIN-A04," a novel oral tyrosine kinase inhibitor (TKI) targeting HER2 Exon20 insertion mutation in NSCLC, will be presented at the upcoming 2023 American Cancer Research Association meeting inOr...
2023-02-07 12:23
1360
Hinova Receives FDA Proceed Authorization for its IND Application for HP518, an Orally Bioavailable Chimeric Degrader Targeting Androgen Receptor for Prostate Cancer Treatment
WILMINGTON, Del., Feb. 6, 2023 /PRNewswire/ -- Hinova Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focusing on developing novel therapeutics for cancers and metabolic diseases, recently announced that the U.S. Food and Drug Administration (FDA) has cleared the company's inves...
2023-02-06 21:10
1831
Inmagene receives IND clearance for IMG-008, a long-acting IL-36R mAb
SAN DIEGO, SHANGHAI and SYDNEY, Feb. 6, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene") announced that the U.S. Food and Drug Administration (FDA) recently granted the initial investigational new drug (IND) application for its drug candidate IMG-008, a long-acting anti-IL-36R antib...
2023-02-06 18:00
2063
Ground-breaking results in Phase 2 scleroderma study by Certa Therapeutics demonstrates improvement in more than 60% of patients
* Data from Certa Therapeutics' Phase 2 clinical trial with development candidate FT011 demonstratesclinically meaningful improvements for more than 60 percent of patients with scleroderma after 12 weeks of treatment; * Clinically meaningful improvements were reported in CRISS (the key compos...
2023-02-06 13:01
1865
Daewoong Pharmaceutical begins the first administration of the Bersiporocin, new treatment for idiopathic pulmonary fibrosis, as Phase II clinical trial
- Evaluation of Bersiporocin's safety and efficacy against a total of 102 patients over 24 weeks - Development of treatment for pulmonary fibrosis which is unsatisfactory and in high demand, and anticipation for extended adaptability against various rare fibrosis diseases SEOUL, South Korea, Fe...
2023-02-06 13:00
1771
Gracell Biotechnologies Announces FDA Clearance of the IND Application for Phase 1b/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Relapsed/Refractory Multiple Myeloma
BCMA/CD19 dual-targeting FasTCAR-T GC012F has demonstrated deep responses and favorable safety profile in proof of concept clinical studies Company plans to initiate Phase 1b/2 clinical trial in the U.S. in second quarter of 2023 SAN DIEGO Calif., and SUZHOU and SHANGHAI, China, Feb. 3, 2023 /PR...
2023-02-03 20:30
3910
BriSTAR Immunotech to Present at the BIO CEO & Investor Conference
BEIJING and TORONTO, Feb. 2, 2023 /PRNewswire/ -- BriSTAR Immunotech, a clinical-stage cell therapy company, announced today that its Chief Executive Officer,James Pan, Ph.D., will be presenting at the 25th BIO CEO & Investor Conference. The conference will take place at the New York Marriott Mar...
2023-02-02 19:37
2095
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
8288
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7685